The Immunoscore® was developed to evaluate the presence of immune infiltrates in the TME of colon cancer patients and to enable the assessment of the density, location, and types of different immune infiltrate cells such as total T cells (CD3+), cytotoxic T cells (CD8+) in the CT, and the IM. The gene discussed is CD8A; the disease is malignant colon neoplasm.